Fierce Pharma
APRIL 24, 2024
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea had on the upward trajectory of Roche’s Vabysmo? Not much, according to sales figures released by Roche.
Pharmaceutical Technology
APRIL 24, 2024
Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in the Covid-19 vaccines development as the latest phase of a global legal fight that started yesterday (23 April), reported Reuters.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 24, 2024
While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large part to accelerating launches of new drugs like Leqembi and Skyclarys—the C | While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks, the CEO admitted Wednesday that there’s still “a lot of work to do” as the biotech plugs ahead with its “Fit for Growth” savings initiative.
MedCity News
APRIL 24, 2024
More than 33,000 Providence employees filed a class-action complaint against the health system in 2021, alleging that it had been withholding their wages by denying them breaks and rounding down their working hours. Last week, Providence was ordered to pay more than $200 million in damages — a decision that “sends a message to healthcare corporations,” according to an attorney representing the workers.
pharmaphorum
APRIL 24, 2024
A new FDA initiative is seeing how augmented reality and virtual reality (AR/VR) can make patients’ own homes an integral part of the healthcare system
MedCity News
APRIL 24, 2024
Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design. The post It’s Time to Give Patients a Seat at the Table appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
APRIL 24, 2024
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception. The post When Investment Rhymes with Canada appeared first on MedCity News.
pharmaphorum
APRIL 24, 2024
An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use by the NHS in England and Wales.
MedCity News
APRIL 24, 2024
Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer. The post FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer appeared first on MedCity News.
pharmaphorum
APRIL 24, 2024
New biotech Xaira Therapeutics emerges with $1bn in funding for its plan to apply AI to drug discovery in ways hard to achieve with conventional technologies
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
APRIL 24, 2024
The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, The companies will offer a window into some of the promising treatments under development such as different types of cancers to muscular dystrophy. Space is limited so register today! The post Six Biopharma Companies to Watch at MedCity INVEST Pitch Perfect Contest appeared first on MedCity News.
European Pharmaceutical Review
APRIL 24, 2024
in clinical trials [the combination treatment was shown] to halt tumour growth for low-grade gliomas for an average of more than two years” The National Institute for Health and Care Excellence (NICE) has recommended a new targeted drug combination treatment for young people with BRAF V600E mutation-positive glioma. Dabrafenib (Finlee) in combination with trametinib (Spexotras) is indicated for patients aged one and over, based on the agency’s proposal in its final draft guidance.
PharmaTech
APRIL 24, 2024
FDA has granted approval for the use of Novartis’ radioligand therapy, Lutathera, to treat pediatric patients with gastroenteropancreatic neuroendocrine tumors.
MedCity News
APRIL 24, 2024
it is paramount that we address both cholesterol risk and inflammation to reduce the risk of a heart attack or stroke. The post To Further Impede the Progression of Heart Disease, We Must Treat Patients With Anti-Inflammatory Drugs in Combination With Statin Therapy appeared first on MedCity News.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
APRIL 24, 2024
Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets including two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell-mediated disorders.
PharmaTimes
APRIL 24, 2024
According to the World Health Organization, CVDs are responsible for an estimated 17.
pharmaphorum
APRIL 24, 2024
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside China. The new approval covers three separate indications for the drug, alone and in combination with chemotherapy for squamous and non-squamous forms of NSCLC, and covering first- and second-line therapy.
MedCity News
APRIL 24, 2024
Algorithms make it possible for companies to fix prices without explicitly coordinating with one another, posing a new test for regulators policing the market, said Lina Khan, chair of the Federal Trade Commission, during a media event hosted by KFF. The post FTC Chief Says Tech Advancements Risk Healthcare Price Fixing appeared first on MedCity News.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Commerce
APRIL 24, 2024
The latest news for pharma industry insiders.
MedCity News
APRIL 24, 2024
Success requires both novel VBC models as well as moving care beyond the clinic walls to meet patients where they are. The post Patient Engagement Is Essential for Achieving the Goals of Value-Based Care appeared first on MedCity News.
PharmaTimes
APRIL 24, 2024
The progressive neurodegenerative condition is the most common form of dementia
PharmExec
APRIL 24, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a preview on what the nexts steps are after presenting positive data on Coya 302 for the treatment of ALS.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Evolve Your Success
APRIL 24, 2024
Amazing episode to celebrate the National Nurses Week! Unlock the secrets to a thrilling career leap from the frontlines of nursing to the cutting edge of medical sales with our guest, Aaron Kravitz, who brings firsthand insights on making this bold transition. This episode is a treasure trove of advice for nurses seeking to leverage their clinical expertise beyond bedside care, as Aaron outlines how he parlayed his background into a successful role as an Account Executive with 3M.
PharmExec
APRIL 24, 2024
In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, speak about what kind of impact their survey's findings impact will be on the industry.
Pharmaceutical Technology
APRIL 24, 2024
Discover how MacroGenics Inc's patent for compounds targeting IL23A and BAFF can suppress inflammatory responses in subjects in need. Learn about the unique polypeptide compositions and methods outlined in the patent.
PharmExec
APRIL 24, 2024
Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
APRIL 24, 2024
Discover the groundbreaking patent by Seres Therapeutics Inc for a unique composition targeting dysbiosis in mammals. Learn how specific bacterial species in a capsule can inhibit pathogenic bacteria growth.
PharmaTech
APRIL 24, 2024
In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.
Pharmaceutical Technology
APRIL 24, 2024
Discover how Ipsen SA's patented compounds can treat cardiovascular, metabolic, gastrointestinal, and liver diseases. Learn about the method and specific compounds outlined in the recently granted patent.
European Pharmaceutical Review
APRIL 24, 2024
New trial data for a gene therapy presented at the International Myology 2024 Congress has revealed “good” tolerability in Duchenne muscular dystrophy, when combined with transient immunological prophylactic treatment, as well as efficacy data relating to microdystrophin expression and functional improvement. The gene therapy trial for GNT0004 enrolled ambulant (able to walk) boys six to 10 years old, Genethon stated.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
245 
Let's personalize your content